ReviewInternational journal of molecular sciences2022
Cardiac Troponin Biosensor Designs: Current Developments and Remaining Challenges.
Review in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 49 citations in OpenAlex.
- Development and validation of an integrated wearable system for continuous cardiorespiratory monitoring using photoplethysmography and optical respiratory detection.Medical & biological engineering & computing · 2026Article
- High Sensitivity Cardiac Troponin I Detection via MP-Locked Aptamer and Multimeric DNAzyme-Coupled Hyperbranched Hybridization Chain Reaction.Small (Weinheim an der Bergstrasse, Germany) · 2026Article
- Surface Modification of Gold Screen-Printed Electrodes with a Sulfonated Polymer for Improved Electrochemical Detection of Cardiac Troponin I.ACS omega · 2026Article
- [Application of molecularly imprinted polymers-based sensors for determination of acute coronary syndrome biomarkers].Se pu = Chinese journal of chromatography · 2026Review
- Article
- Cardiac Troponin I Biosensors: Innovations in Real-Time Diagnosis of Cardiovascular Diseases.Analytical science advances · 2025Review
- Nanoparticulate Copper Cluster-Mediated Biosensing of Cardiac Biomolecular Markers.Biosensors · 2025Article
- Recent Advances in Metallic Nanostructures-assisted Biosensors for Medical Diagnosis and Therapy.Current topics in medicinal chemistry · 2024Review
- Article
- Integrated multi-omics approach revealed TTNtv c.13254T>G causing dilated cardiomyopathy in mice.PloS one · 2024Article
- Theoretical analysis of immunochromatographic assay and consideration of its operating parameters for efficient designing of high-sensitivity cardiac troponin I (hs-cTnI) detection.Scientific reports · 2023Article
- Methods for detecting of cardiac troponin I biomarkers for myocardial infarction using biosensors: a narrative review of recent research.Journal of thoracic disease · 2023Review
- Article
- Photoelectrochemical Determination of Cardiac Troponin I as a Biomarker of Myocardial Infarction Using a BiBiosensors · 2023Article
- A review of cardiac troponin I detection by surface enhanced Raman spectroscopy: Under the spotlight of point-of-care testing.Frontiers in chemistry · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
Abstract
Acute myocardial infarction (AMI) is considered as one of the main causes of death, threating human lives for decades. Currently, its diagnosis relies on electrocardiography (ECG), which has been proven to be insufficient. In this context, the efficient detection of cardiac biomarkers was proposed to overcome the limitations of ECG. In particular, the measurement of troponins, specifically cardiac troponin I (cTnI) and cardiac troponin T (cTnT), has proven to be superior in terms of sensitivity and specificity in the diagnosis of myocardial damage. As one of the most life-threatening conditions, specific and sensitive investigation methods that are fast, universally available, and cost-efficient to allow for early initiation of evidence-based, living-saving treatment are desired. In this review, we aim to present and discuss the major breakthroughs made in the development of cTnI and cTnT specific biosensor designs and analytical tools, highlighting the achieved progress as well as the remaining challenges to reach the technological goal of simple, specific, cheap, and portable testing chips for the rapid and efficient on-site detection of cardiac cTnI/cTnT biomarkers in order to diagnose and treat cardiovascular diseases at an incipient stage.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.